Skip to content

Startup & venture capital news

Yingjiexin Medical raises RMB 200m Series B

CICC Capital affiliated fund leads drug delivery device financing

By /

LinkedInX
Yingjiexin Medical: Yingjiexin Medical raises RMB 200m Series B

Yingjiexin Medical announced an RMB 200 million Series B on 2 November 2026, led by a fund affiliated with CICC Capital. Zhuhai Technology Industry Group, Co Stone Capital, Qiming Venture Partners, Houxin Health Investment and Yingyue Fund joined, while GRC SinoGreen Capital reinvested. The Shanghai company develops precision drug delivery devices, including disposable and reusable injection pens and automatic injectors for biologic medicines. Yingjiexin said the proceeds will expand production and delivery, accelerate new products, and support overseas registration and sales. The amount is current equity funding, not cumulative capital, a grant or a fundraising target.

Keep reading

More Funding

All stories